Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

ceftolozane/tazobactam

- PMLiVE

Scientists uncover new drug target in fight against antimicrobial resistance

The discovery could lead to improved treatments for bacterial infections

- PMLiVE

EMA reaffirms guidance on paracetamol use during pregnancy

The guidance follows recent US comments about a possible link to autism

- PMLiVE

Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

- PMLiVE

EMA orphan drug designation given to ReAlta for graft-versus-host disease therapy

This follows preliminary results from the company's ongoing phase 2 trial

- PMLiVE

Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11

The reference medicine holds approvals for multiple HER2-positive breast cancer indications

- PMLiVE

GSK’s antibiotic Blujepa granted FDA approval to treat urinary tract infections

Blujepa is the first in a new class of oral antibiotics for uncomplicated UTIs in nearly 30 years

- PMLiVE

AbbVie announces FDA approval of antibiotic combination for intra-abdominal infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health

Biogen Idec building

Biogen’s higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA

The neuromuscular disease affects approximately one in every 10,000 babies worldwide

- PMLiVE

UK study shows RSV vaccine could reduce antibiotic use and antimicrobial resistance

The new analysis found that RSV infections lead to 640,000 antibiotic prescriptions every year

- PMLiVE

Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation

The updated vaccine was shown to generate an improved response against currently circulating variants

- PMLiVE

New genomic technique could improve antibiotic-resistant bacteria tracking in hospitals

The sequencing method is able to track the spread of multiple bacteria at the same time

- PMLiVE

Paratek announces positive late-stage results for Nuzyra in bacterial pneumonia

The condition, caused by various bacteria, affects more than 900,000 people in the US every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links